Patiromer vs Sodium zirconium cyclosilicate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Gastrointestinal potassium binder · full Chronic Kidney Disease pipeline
Patiromer · Veltassa
Marketed by CSL Limited and partners
NCT01810939 · Phase 3 · completed
The study enrolled 243 participants and used single-blind treatment; Part A assessed patiromer without a concurrent comparator, while Part B randomized 107 patiromer responders to continued patiromer or placebo. Both primary serum-potassium comparisons favored patiromer with p<0.001, but serum potassium is a laboratory surrogate rather than a hard clinical or endoscopic endpoint.
Next expected readout: December 2026 · NCT06256991 (registry estimate)
Reported efficacy
Change in Serum Potassium From Part A Baseline to Part A Week 4; Change in Serum Potassium From Part B Baseline (Part B Baseline to Part B Week 4 or first local laboratory serum potassium < 3.8 mEq/L or ≥ 5.5 mEq/L): Change in Serum Potassium From Part A Baseline to Part A Week 4 (Part A Baseline to Part A Week 4): Part A Patiromer -1.01 mEq/L (Standard Error 0.031) (met)
Result source: NCT01810939
Sodium zirconium cyclosilicate · Lokelma
Marketed by AstraZeneca
NCT05056727 · Phase 3 · terminated
This was a large, well-designed, randomized, quadruple-blind, placebo-controlled trial using an objective kidney-function measure as its primary endpoint, but neither of its two primary comparisons (total or chronic eGFR slope) showed a statistically significant difference between sodium zirconium cyclosilicate and placebo.
Next expected readout: December 2026 · NCT06578078 (registry estimate)
Reported efficacy
Total eGFR Slope (Coprimary Analysis #1) (Baseline (Maintenance phase) to visit 17 (week 69)); Chronic eGFR Slope (Coprimary Analysis #2) (12 weeks to visit 17 (week 69)): Total eGFR Slope (Coprimary Analysis #1) (Baseline (Maintenance phase) to visit 17 (week 69)): Maintenance Phase: SZC -5.2975 mL/min/(1.73 m2)/yr (95% CI -6.6854 to -3.9097) vs Maintenance Phase: Placebo -4.5622 mL/min/(1.73 m2)/yr (95% CI -5.9969 to -3.1275) (missed)
Result source: NCT05056727
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Patiromer | Sodium zirconium cyclosilicate |
|---|---|---|
| Kidney composite outcome | —Not posted · NCT05136664 | —Not posted · NCT05004363 |
| UACR, % change | —Not posted · NCT05136664 | —Not posted · NCT05004363 |
| eGFR slope | —Not posted · NCT05136664 | —Not posted · NCT05004363 |
| Haemoglobin, change | —Not posted · NCT05136664 | —Not posted · NCT05004363 |
Kidney composite outcome
- Patiromer
- —Not posted · NCT05136664
- Sodium zirconium cyclosilicate
- —Not posted · NCT05004363
UACR, % change
- Patiromer
- —Not posted · NCT05136664
- Sodium zirconium cyclosilicate
- —Not posted · NCT05004363
eGFR slope
- Patiromer
- —Not posted · NCT05136664
- Sodium zirconium cyclosilicate
- —Not posted · NCT05004363
Haemoglobin, change
- Patiromer
- —Not posted · NCT05136664
- Sodium zirconium cyclosilicate
- —Not posted · NCT05004363
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Patiromer: 4 of 4 rows · Sodium zirconium cyclosilicate: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Patiromer | Sodium zirconium cyclosilicate |
|---|---|---|
| Dropout rate | 9.9%Part A Patiromera NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 13 more results—Part B Patiromer NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 5.9% NCT03781089 · Phase 4 · registry result, not featured evidence 33.3% NCT03183778 · Phase 4 · registry result, not featured evidence · combination 25% NCT02933450 · Phase 4 · registry result, not featured evidence 3.7% NCT03326583 · Phase 2 · registry result, not featured evidence 2% NCT03071263 · Phase 2 · registry result, not featured evidence 24.3%8.4 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 46.7%33.6 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 32.4%25.2 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 25%25.2 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 31.1%16.8 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 34.6%16.8 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 11.1% NCT01130597 · Phase 2 · registry result, not featured evidence | —b NCT05056727 · Phase 3 · combination · Chronic Kidney Disease · phase 3 show 4 more results— NCT05347693 · Phase 4 · registry result, not featured evidence 0%10 g Three Times Daily NCT01493024 · Phase 2 · registry result, not featured evidence 0%3 g Three Times Daily NCT01493024 · Phase 2 · registry result, not featured evidence 0%0.3 g Three Times Daily NCT01493024 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 4.1%Part A Patiromera NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 13 more results—Part B Patiromer NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 — NCT03781089 · Phase 4 · registry result, not featured evidence — NCT03183778 · Phase 4 · registry result, not featured evidence · combination — NCT02933450 · Phase 4 · registry result, not featured evidence — NCT03326583 · Phase 2 · registry result, not featured evidence 0.7% NCT03071263 · Phase 2 · registry result, not featured evidence 5.4%8.4 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 6.7%33.6 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 9.5%25.2 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 7.1%25.2 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 2.7%16.8 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 7.7%16.8 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 6.3% NCT01130597 · Phase 2 · registry result, not featured evidence | —b NCT05056727 · Phase 3 · combination · Chronic Kidney Disease · phase 3 show 4 more results— NCT05347693 · Phase 4 · registry result, not featured evidence —10 g Three Times Daily NCT01493024 · Phase 2 · registry result, not featured evidence —3 g Three Times Daily NCT01493024 · Phase 2 · registry result, not featured evidence —0.3 g Three Times Daily NCT01493024 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 1.2%Part A Patiromera NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 13 more results0%Part B Patiromer NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 11.8% NCT03781089 · Phase 4 · registry result, not featured evidence 0% NCT03183778 · Phase 4 · registry result, not featured evidence · combination 0% NCT02933450 · Phase 4 · registry result, not featured evidence 40.7% NCT03326583 · Phase 2 · registry result, not featured evidence 0.7% NCT03071263 · Phase 2 · registry result, not featured evidence 12.2%8.4 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 13.3%33.6 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 13.7%25.2 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 17.9%25.2 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 13.7%16.8 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 23.1%16.8 g/d NCT01371747 · Phase 2 · registry result, not featured evidence 9.5% NCT01130597 · Phase 2 · registry result, not featured evidence | 18.4%b NCT05056727 · Phase 3 · combination · Chronic Kidney Disease · phase 3 show 4 more results42.6% NCT05347693 · Phase 4 · registry result, not featured evidence 0%10 g Three Times Daily NCT01493024 · Phase 2 · registry result, not featured evidence 0%3 g Three Times Daily NCT01493024 · Phase 2 · registry result, not featured evidence 0%0.3 g Three Times Daily NCT01493024 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a constipation 10.7% (placebo 0%) hypertension 1.6% (placebo 5.8%) headache 0.8% (placebo 7.7%) NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 show 12 more resultsconstipation 3.6% (placebo 0%) headache 3.6% (placebo 7.7%) influenza 1.8% (placebo 5.8%) NCT01810939 · Phase 3 · monotherapy · Chronic Kidney Disease · phase 3 bloody stools/diarrhea 5.9% constipation 5.9% emergency room visit due to shortness of breath 5.9% NCT03781089 · Phase 4 · registry result, not featured evidence constipation 0% diarrhea 0% hypomagnesemia 0% NCT03326583 · Phase 2 · registry result, not featured evidence renal impairment 8.8% (placebo 6.8%) diarrhoea 6.1% (placebo 5.4%) headache 6.1% (placebo 7.4%) NCT03071263 · Phase 2 · registry result, not featured evidence 8.4 g/d diarrhoea 8.1% hypertension 6.8% renal failure chronic 6.8% NCT01371747 · Phase 2 · registry result, not featured evidence 33.6 g/d renal failure chronic 20% constipation 16.7% hypomagnesaemia 16.7% NCT01371747 · Phase 2 · registry result, not featured evidence 25.2 g/d hypomagnesaemia 8.2% anaemia 5.5% constipation 5.5% NCT01371747 · Phase 2 · registry result, not featured evidence 25.2 g/d hypomagnesaemia 14.3% renal failure chronic 10.7% angina pectoris 7.1% NCT01371747 · Phase 2 · registry result, not featured evidence 16.8 g/d hypertension 9.6% diarrhoea 6.8% hypomagnesaemia 6.8% NCT01371747 · Phase 2 · registry result, not featured evidence 16.8 g/d hypertension 15.4% diarrhoea 11.5% cardiac failure chronic 7.7% NCT01371747 · Phase 2 · registry result, not featured evidence abdominal discomfort 6.3% NCT01130597 · Phase 2 · registry result, not featured evidence | b hypokalaemia 12.3% (placebo 0.3%) hyperkalaemia 6.4% (placebo 26.2%) hypertension 5% (placebo 3.7%) NCT05056727 · Phase 3 · combination · Chronic Kidney Disease · phase 3 show 4 more resultshyperkalaemia 17.6% renal impairment 7.4% cardiac failure 5.9% NCT05347693 · Phase 4 · registry result, not featured evidence 10 g Three Times Daily vomiting 12.5% (placebo 3.3%) nausea 8.3% (placebo 3.3%) urinary tract infection 8.3% (placebo 0%) NCT01493024 · Phase 2 · registry result, not featured evidence 3 g Three Times Daily aspartate aminotransferae increased 4.2% (placebo 0%) constipation 4.2% (placebo 0%) nausea 4.2% (placebo 3.3%) NCT01493024 · Phase 2 · registry result, not featured evidence 0.3 g Three Times Daily abdominal pain 8.3% (placebo 0%) diarrhea 8.3% (placebo 0%) abdominal tenderness 0% (placebo 3.3%) NCT01493024 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 12 of these studies.
- bPopulation comparability has not been reviewed for 4 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Patiromer
show 24 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 23 more results
+ 2 further endpoints in the CSV export.
Sodium zirconium cyclosilicate
show 1 more result
show 1 more result
show 8 more results
show 5 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Patiromer's landscape · Sodium zirconium cyclosilicate's landscape